Amicus Therapeutics, a prominent biotechnology firm, is committed to discovering, developing, and providing treatments for rare illnesses. Through its extensive portfolio of commercial products and product candidates, including Galafold, an oral precision medicine targeting adults with Fabry disease, Amicus is working to make a positive impact on patients' lives. AT-GAA, which represents a groundbreaking treatment paradigm for Pompe disease, and enzyme replacement therapies are among the company's other promising projects. Amicus also maintains collaboration and license agreements with several prominent organizations, including Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. Since its inception in 2002, the company has been based in Philadelphia, Pennsylvania.